Do commonly used clinical trial designs reflect clinical reality?

Area of Science:

• Clinical trial methodology
• Biostatistics
• Hematology Oncology

Background:

• Standard clinical trial designs (Phase II, III) often prioritize statistical significance over medical relevance.
• Current designs may not align with patient priorities, such as comparing new treatments directly.
• Traditional methods are ill-suited for rapidly progressing diseases like acute leukemias.

Purpose of the Study:

• To highlight the disconnect between current clinical trial designs and clinical reality.
• To propose alternative clinical trial designs that better reflect patient and physician perspectives.
• To introduce Bayesian statistical approaches as a more suitable alternative for certain clinical contexts.

Main Methods:

• Critique of existing randomized Phase III and Phase II clinical trial designs.
• Discussion of limitations including statistical focus, sample size constraints, and single-outcome focus.
• Proposal of Bayesian statistical methods and alternative trial designs.

Main Results:

• Common clinical trial designs oversimplify medical practice and do not adequately represent patient views.
• P-value based statistics discourage learning from previous patients within a trial.
• Randomization between treatments is often delayed until late phases, missing opportunities for early comparison.

Conclusions:

• Bayesian statistical approaches offer a more realistic framework for clinical trial design, especially for acute myeloid leukemia.
• Alternative designs can better incorporate patient preferences and physician insights.
• Adopting new designs can lead to more medically relevant and efficient clinical research.